Scarica l'app Stockscreener
19.60
2.40%
0.46
Pre-mercato:
19.34
-0.26
-1.33%
Precedente Chiudi:
$19.14
Aprire:
$19.42
Volume 24 ore:
573.65K
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.39B
Reddito:
$80.89M
Utile/perdita netta:
$-144.73M
Rapporto P/E:
-7.3684
EPS:
-2.66
Flusso di cassa netto:
$-83.87M
1 W Prestazione:
+5.38%
1M Prestazione:
-1.16%
6M Prestazione:
-5.68%
1 anno Prestazione:
+140.20%
Intervallo 1D:
$19.32
$20.15
Intervallo di 1 settimana:
$18.75
$20.50
Portata 52W:
$7.65
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Confronta NRIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
19.60 | 1.39B | 80.89M | -144.73M | -83.87M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-11 | Iniziato | Jefferies | Buy |
| 2024-09-06 | Ripresa | Robert W. Baird | Outperform |
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Nurix Therapeutics appoints new chief commercial officer - Investing.com
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer - The Manila Times
Nurix Therapeutics Taps Former Ibrutinib Commercial Chief to Lead NX-5948 Launch Strategy - StockTitan
Nurix Therapeutics (NASDAQ:NRIX) Given "Overweight" Rating at Stephens - MarketBeat
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth - Yahoo Finance
Learn to Evaluate (NRIX) using the Charts - Stock Traders Daily
Nurix Therapeutics Unveils 2025 Objectives and Achievements - TipRanks
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases - The Manila Times
Nurix's NX-5948 Cancer Drug Achieves 75% Response Rate, Secures Fast Track Status - StockTitan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 7.1%Time to Sell? - MarketBeat
Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation (NASDAQ:NRIX) - Seeking Alpha
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 3.9%What's Next? - MarketBeat
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Nurix Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
(NRIX) Trading Report - Stock Traders Daily
Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me - Seeking Alpha
Nurix therapeutics chief legal officer sells $112k in stock By Investing.com - Investing.com Nigeria
Nurix therapeutics chief legal officer sells $112k in stock - Investing.com India
How the (NRIX) price action is used to our Advantage - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Geode Capital Management LLC - Defense World
Franklin Resources Inc. Has $2.77 Million Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Geode Capital Management LLC Has $32.54 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Barclays PLC Increases Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Barclays PLC Buys 56,190 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 3.2%Here's Why - MarketBeat
Jane Street Group LLC Has $3.54 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
State Street Corp Sells 337,262 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia - The Manila Times
Nurix Therapeutics Receives U.S. FDA Fast Track Designation - GlobeNewswire
Nurix's BTK Degrader NX-5948 Earns FDA Fast Track Status for Rare Blood Cancer Treatment - StockTitan
State Street Corp Cuts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
NX-5948 Earns Fast Track Designation in R/R Waldenström Macroglobulinemia - Cancer Network
Nurix Therapeutics' SWOT analysis: btk degrader stock shows promise amid challenges - Investing.com
Lord Abbett & CO. LLC Purchases Shares of 350,640 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $30.35 - MarketBeat
When (NRIX) Moves Investors should Listen - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stake Boosted by The Manufacturers Life Insurance Company - Defense World
BTIG Initiates Coverage of Nurix Therapeutics (NRIX) with Buy Recommendation - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Fmr LLC - MarketBeat
Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers? - MSN
Nurix Therapeutics (NASDAQ:NRIX) Given New $35.00 Price Target at HC Wainwright - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Wellington Management Group LLP - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Coverage Initiated at BTIG Research - MarketBeat
Nurix Therapeutics' (NRIX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Nurix Therapeutics Reports Promising Trial Results for NX-5948 - TipRanks
Nurix Therapeutics's SWOT analysis: btk degrader stock shows promise amid challenges By Investing.com - Investing.com South Africa
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting - The Manila Times
Nurix Therapeutics's SWOT analysis: btk degrader stock shows promise amid challenges - Investing.com India
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nurix Therapeutics Inc Azioni (NRIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Jan 02 '25 |
Sale |
19.50 |
5,760 |
112,295 |
28,084 |
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):